H1 FY27 PAT Rises 80.8% YoY to ₹5.31 Cr; Revenue Up 42.4% to ₹45.09 Cr
Biopol Chemicals reported its unaudited standalone results for the half year ended September 30, 2026 (H1 FY27). Revenue from operations grew 42.4% YoY to ₹4,509.47 lakhs (₹45.09 cr) compared to ₹3,165.73 lakhs in H1 FY26. Net profit surged 80.8% YoY to ₹530.62 lakhs (₹5.31 cr) from ₹293.42 lakhs, with basic EPS increasing to ₹4.91 from ₹3.71. The balance sheet reflects ongoing expansion, with Capital Work-in-Progress surging to ₹1,050.88 lakhs compared to ₹12.00 lakhs as of March 31, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுBiopol Chemicals declared its H1 FY27 financial performance showing strong top-line and bottom-line growth alongside significant capex spending.
ஏன் இது முக்கியம்Demonstrates strong operational momentum with over 80% net profit growth and aggressive capacity additions indicated by the surge in capital work-in-progress.
H1 FY27 Revenue: ₹4,509.47 லட்சம்H1 FY27 PAT: ₹530.62 லட்சம்H1 FY27 EPS: ₹4.91Capital Work-in-progress: ₹1,050.88 லட்சம்Short-term Borrowings: ₹1,324.19 லட்சம்
📅 குறுகிய காலம்The strong operational performance is likely to be received positively by the market, though investors will weigh the surge in short-term debt taken to fund operations and capex.
📈 நீண்ட காலம்The ₹10.51 cr addition to CWIP relative to existing net PPE of ₹14.35 cr suggests substantial capacity scaling that could drive future revenue expansion.
⚠ அபாய எச்சரிக்கைகள்
- Sharp increase in short-term borrowings from ₹3.41 cr to ₹13.24 cr
- Inventory build-up from ₹19.61 cr to ₹25.35 cr impacting working capital
👀 கவனிக்க வேண்டியவை
Track the commercialization timeline of the ₹10.51 cr ongoing capital work-in-progress and monitor whether elevated short-term borrowings normalize as operating cash flows ramp up.
